IQVIA Holdings, Inc.

Valuation Analysis

About the Company

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segm

IQVIA Holdings, Inc. Stock at a Glance

IQVIA Holdings, Inc. (IQV) is currently trading at $181.46 with a market capitalization of $30.3B. The trailing P/E ratio stands at 22.51x, with a forward P/E of 12.78x. The 52-week range spans from $153.01 to $247.05; the current price is 26.5% below the yearly high. Year-over-year revenue growth stands at +8.4%. The net profit margin stands at 8.33%.

💰 Dividend

IQVIA Holdings, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

19 analysts rate IQVIA Holdings, Inc. (IQV) on consensus: Strong Buy. The average price target is $226.95, implying +25.07% from the current price. Analyst price targets range from $195.00 to $287.00.

IQVIA Holdings, Inc.: The Investment Case in Detail

IQVIA Holdings, Inc. (IQV) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Wall Street consensus sits at Strong Buy with an average price target implying roughly 25.07% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

The debt-to-equity ratio of 255.43% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valuation in Context

With a PEG ratio of 0.73, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 12.78x is meaningfully below the trailing 22.51x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 25.07% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to market-like volatility, higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy IQVIA Holdings, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.